CIN No.: L24230TG1995PLC020093

Admn. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail: concorddrugsltd@gmail.com Website: www.concorddrugs.in

To,

Date: 26.05.2020

BSE Limited

P.J. Towers, Dalal Street

Mumbai - 400001

Dear Sir/Madam,

Please find enclosed the yearly disclosure under regulation 31(4) of SEBI (Substantial Acquisition of

Shares and Takeovers) Regulation, 2011 received from the Promoters of the Company for the year ended on 31st March, 2020.

This is for the information and records of the Exchange, please.

Yours sincerely,

For Concord Drugs Limited

S. NAGI REDDY

Whole time Director

DIN: 01764665.

Date: 26.05.2020

BSE Limited	The Audit Committee
P.J.Towers, Dalal Street	Concord Drugs Limited
Mumbai- 400001	Survey No.249, Brahmanpally Village,
	HayatnagarMandal, R.R. Dist, Hyderabad,
	Telangana, 501511

Dear Sir/Madam

Sub: Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers)
Regulations, 2011

Pursuant to the provision of the Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, we hereby declare that we promoters hold collectively 37,40,500 shares of Concord Drugs Limited as on March 31, 2020 and we have not made any encumbrance of shares, directly or indirectly, during the financial year ended March 31, 2020.

Kindly take the same in the records of the Exchange.

For and on behalf of the promoters

Place: Hyderabad

Date: 26.05.2020

5, N- May